EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk-Aware Computational Prioritization and Validation Route Design for Medicine–Food Homology Plant Compounds in a Parkinson’s Disease Context

Jinhao Zou, Siyi Wang, Jingjiao Yong, Liangyu Yan, Hong Hui, Ye Sun

BioTech · 10.08.2026 · 15 (3) · 66

DOI: 10.3390/biotech15030066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioTech, online erschienen am 10.08.2026. Verfasst von Jinhao Zou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Dryness Syndrome in Chinese Medicine, Ministry of Education, Ningxia Medical University, Yinchuan 750004, China. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ningxia Medical University, Science and Technology Department of Ningxia, Natural Science Foundation of Ningxia Hui Autonomous Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Network pharmacology studies of medicine–food homology plants have identified broad injury response pathways and hubs that cannot support compound-level or Parkinson’s disease (PD)-specific claims. We developed a traceable, non-weighted framework that separates regulatory provenance, PD-context evidence, structural support, and safety/developability liabilities. A ten-plant feasibility panel was locked before overlap with a 1631-gene PD union, yielding 382 plant-associated targets and 190 strict intersections. Leave-one-plant-out analysis retained 173–190 targets, whereas disease source and threshold stress tests showed curation dependence. Whole-blood classifiers showed modest five-fold discrimination (area under the curve, 0.606–0.682) and were excluded from candidate decisions. Redocking-validated AutoDock Vina and protein–ligand interaction fingerprints retained baicalein–MMP9, baicalein–AKT1, and baicalein–BCL2 as caution-tagged follow-up pairs. Quercetin–MMP9 was retained as a liability-tagged comparator, while KCNH2 relations were safety-only. Because no biological validation is presented, these pairs remain hypotheses for prospective MPP+-treated SH-SY5Y testing with orthogonal injury, dopaminergic phenotypes, target dependency, material confirmation and safety controls. Baicalein remains source-pending for the material chain.

Schlagwörter

Stichwörter der Autor:innen

Parkinson’s diseasebaicaleinevidence domain assessmentexperimental validation routefeasibility panelmedicine–food homologymolecular dockingreproducibilitysource provenance

Autor:innen und Institutionen

  • Key Laboratory of Dryness Syndrome in Chinese Medicine, Ministry of Education, Ningxia Medical University, Yinchuan 750004, China.
  • College of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
  • College of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan 750004, China.

Förderung

  • Ningxia Medical University
  • Science and Technology Department of Ningxia
  • Natural Science Foundation of Ningxia Hui Autonomous Region
  • Key Research and Development Program of Ningxia Hui Autonomous Region

Zitieren

APA

Zou, J., Wang, S., Yong, J., Yan, L., Hui, H., & Sun, Y. (2026). Risk-Aware Computational Prioritization and Validation Route Design for Medicine–Food Homology Plant Compounds in a Parkinson’s Disease Context. BioTech, 15(3), 66. https://doi.org/10.3390/biotech15030066

Vancouver

Zou J, Wang S, Yong J, Yan L, Hui H, Sun Y. Risk-Aware Computational Prioritization and Validation Route Design for Medicine–Food Homology Plant Compounds in a Parkinson’s Disease Context. BioTech. 2026;15(3):66. doi:10.3390/biotech15030066

BibTeX
@article{Zou2026,
  author = {Zou, Jinhao and Wang, Siyi and Yong, Jingjiao and Yan, Liangyu and Hui, Hong and Sun, Ye},
  title = {Risk-Aware Computational Prioritization and Validation Route Design for Medicine–Food Homology Plant Compounds in a Parkinson’s Disease Context},
  journal = {BioTech},
  year = {2026},
  volume = {15},
  number = {3},
  pages = {66},
  doi = {10.3390/biotech15030066}
}
Kostenlos starten →